Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
33.30
-0.27 (-0.79%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Kymera Therapeutics stock have an average target of 56.69, with a low estimate of 36 and a high estimate of 74. The average target predicts an increase of 70.27% from the current stock price of 33.30.
Analyst Consensus: Buy
* Price targets were last updated on Mar 13, 2025.
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 4 | 5 | 5 |
| Buy | 6 | 7 | 7 | 5 | 5 | 5 |
| Hold | 4 | 4 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 16 | 15 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $52 | Strong Buy | Initiates | $52 | +56.18% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $54 → $60 | Strong Buy | Maintains | $54 → $60 | +80.21% | Feb 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $60 | Buy | Reiterates | $60 | +80.21% | Jan 21, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $60 | Buy | Maintains | $60 | +80.21% | Dec 27, 2024 |
| BTIG | BTIG | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +80.21% | Dec 10, 2024 |
Financial Forecast
Revenue This Year
54.72M
from 47.07M
Increased by 16.24%
Revenue Next Year
66.98M
from 54.72M
Increased by 22.41%
EPS This Year
-3.77
from -2.98
EPS Next Year
-4.15
from -3.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 131.9M | 157.3M | 245.7M | ||
| Avg | 54.7M | 67.0M | 87.8M | ||
| Low | 13.3M | n/a | -37.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 180.2% | 187.5% | 266.9% | ||
| Avg | 16.2% | 22.4% | 31.1% | ||
| Low | -71.7% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.74 | -3.27 | -2.86 | ||
| Avg | -3.77 | -4.15 | -4.17 | ||
| Low | -4.63 | -5.87 | -7.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.